Technical Analysis for KROS - Keros Therapeutics, Inc.

Grade Last Price % Change Price Change
C 63.86 -5.18% -3.49
KROS closed down 5.18 percent on Monday, March 18, 2024, on 89 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish -5.18%
Crossed Above 20 DMA Bullish -5.18%
Pocket Pivot Bullish Swing Setup -5.18%
Volume Surge Other -5.18%
Fell Below 20 DMA Bearish -1.50%
Boomer Buy Setup Bullish Swing Setup -5.62%
Inside Day Range Contraction -5.62%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 9 hours ago
60 Minute Opening Range Breakdown about 11 hours ago
Fell Below 20 DMA about 11 hours ago
Down 3% about 13 hours ago
Down 2 % about 13 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Keros Therapeutics, Inc. Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Rare Diseases Bone Disorders Hypertension Therapeutic Products Hematology Pulmonary Arterial Hypertension Anemia Myelodysplastic Syndrome Osteoporosis Syndromes Genodermatoses Skeletal Disorders Molecule Product Bone Disease Thrombocytopenia Myelofibrosis Hematopathology Musculoskeletal Disorders Osteogenesis Imperfecta

Is KROS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 73.0
52 Week Low 27.03
Average Volume 439,442
200-Day Moving Average 41.56
50-Day Moving Average 59.09
20-Day Moving Average 66.26
10-Day Moving Average 67.05
Average True Range 3.67
RSI (14) 50.50
ADX 34.3
+DI 19.22
-DI 17.13
Chandelier Exit (Long, 3 ATRs) 61.98
Chandelier Exit (Short, 3 ATRs) 67.24
Upper Bollinger Bands 72.32
Lower Bollinger Band 60.20
Percent B (%b) 0.3
BandWidth 18.29
MACD Line 2.43
MACD Signal Line 3.32
MACD Histogram -0.8822
Fundamentals Value
Market Cap 2.17 Billion
Num Shares 34 Million
EPS -4.96
Price-to-Earnings (P/E) Ratio -12.88
Price-to-Sales 229097.34
Price-to-Book 6.14
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 69.11
Resistance 3 (R3) 69.61 68.37 68.24
Resistance 2 (R2) 68.37 67.03 68.12 67.94
Resistance 1 (R1) 66.11 66.20 65.49 65.61 67.65
Pivot Point 64.87 64.87 64.56 64.62 64.87
Support 1 (S1) 62.61 63.53 61.99 62.11 60.07
Support 2 (S2) 61.37 62.70 61.12 59.78
Support 3 (S3) 59.11 61.37 59.49
Support 4 (S4) 58.61